Su

SUBJECTIVE GLOBAL ASSESSMENT
SUBSTANCE USE STATUS (MOTHER AT BOOKING)
SUMMARY ASSESSMENT OF CHARACTERISTICS RATING 13 SCORE
SUMMARY ASSESSMENT OF CHARACTERISTICS RATING A SCORE
SUMMARY ASSESSMENT OF CHARACTERISTICS RATING B SCORE
SUMMARY ASSESSMENT OF CHARACTERISTICS RATING C SCORE
SUMMARY ASSESSMENT OF CHARACTERISTICS RATING D SCORE
SUMMARY ASSESSMENT OF CHARACTERISTICS RATING E SCORE
SUPERVISED COMMUNITY TREATMENT END REASON
SUPERVISED COMMUNITY TREATMENT PATIENTS (LEARNING DISABILITY PRIMARY REASON FOR USING ACT - FEMALE)
SUPERVISED COMMUNITY TREATMENT PATIENTS (LEARNING DISABILITY PRIMARY REASON FOR USING ACT - MALE)
SUPERVISED COMMUNITY TREATMENT PATIENTS (TOTAL - FEMALE)
SUPERVISED COMMUNITY TREATMENT PATIENTS (TOTAL - MALE)
SUPERVISED COMMUNITY TREATMENTS STARTED FOR TYPE (FEMALE)
SUPERVISED COMMUNITY TREATMENTS STARTED FOR TYPE (MALE)
SUPPORT STATUS (MOTHER AT BOOKING)
SURGICAL DEFAULT TECHNIQUE INDICATOR
SURGICAL URGENCY
SURVEILLANCE DATE (DIALYSIS ACCESS)
SURVEILLANCE TECHNIQUE (DIALYSIS ACCESS)
SUSPENSION END DATE
SUSPENSION END DATE STATUS
SUSPENSION START DATE
SUSPENSION START DATE STATUS
SYMPTOMS FIRST NOTED DATE
SYNCHRONOUS TUMOUR INDICATOR
SYSTEMIC ANTI-CANCER DRUG NAME
SYSTEMIC ANTI-CANCER THERAPY ADMINISTRATION DATE
SYSTEMIC ANTI-CANCER THERAPY DRUG ROUTE OF ADMINISTRATION
SYSTEMIC ANTI-CANCER THERAPY PROGRAMME NUMBER
SYSTEMIC ANTI-CANCER THERAPY REGIMEN MODIFICATION INDICATOR (DAYS REDUCED)
SYSTEMIC ANTI-CANCER THERAPY REGIMEN MODIFICATION INDICATOR (DOSE REDUCTION)
SYSTEMIC ANTI-CANCER THERAPY REGIMEN MODIFICATION INDICATOR (TIME DELAY)
SYSTOLIC BLOOD PRESSURE
SYSTOLIC BLOOD PRESSURE (POST HAEMODIALYSIS)
SYSTOLIC BLOOD PRESSURE (PRE-HAEMODIALYSIS)